Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab

Luisa Ricciardi; Daniel Griscti Soler; Alessandra Bennici; Silvia Brunetto; Giovanni Pioggia; Sebastiano Gangemi

doi:10.3389/fphar.2022.858344

Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab

Front Pharmacol. 2022 Apr 7:13:858344. doi: 10.3389/fphar.2022.858344. eCollection 2022.

Authors

Luisa Ricciardi¹, Daniel Griscti Soler¹, Alessandra Bennici¹, Silvia Brunetto¹, Giovanni Pioggia², Sebastiano Gangemi¹

Affiliations

¹ Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, Policlinico "G. Martino", University of Messina, Messina, Italy.
² Institute for Biomedical Reasearch and Innovation, National Research Council of Italy (IRIB-CNR), Messina, Italy.

Abstract

Background: Traditionally, Eosinophilic Granulomatosis with Polyangiitis (EGPA) has been treated with systemic corticosteroids and immunosuppressants. In recent years, therapeutic efforts have been directed towards targeting eosinophils which represent a major player in the pathogenesis of EGPA. In 2017 the Food and Drug Administration (FDA) approved mepolizumab, a humanized monoclonal antibody targeting interleukin 5 (IL-5) which reduces the production and survival of eosinophils, already used to treat severe eosinophilic asthma, for the management of EGPA. Benralizumab is a humanized monoclonal antibody that targets the IL-5 receptor and is indicated in the treatment of severe eosinophilic asthma. Case description: We describe the case of a young female with a positive history of severe eosinophilic asthma associated with EGPA, treated successfully with benralizumab.

Keywords: EGPA; asthma; benralizumab; eosinophils; young adult.

Publication types

Case Reports